Accure Therapeutics appoints Dr Philippe Monteyne as Chairman of the Board of Directors

Accure Therapeutics, a translational R&D engine in neuroscience developing First-in-class peptidomimetics with potential to be disease modifying therapies, strengthen its governance with a seasoned professional in life sciences

Barcelona, January 24, 2024  — Accure Therapeutics, a clinical-stage biotechnology company focused on delivering innovative CNS therapeutics, today announced it has appointed Dr. Philippe Monteyne as chairman of the Accure Therapeutics Board of Directors.

“We are excited to welcome Philippe to Accure’s Board of Directors as chairman. With more than 30 years of diverse experience across the pharmaceutical landscape, Philippe brings a track record of substantial accomplishment across our sector as a drug developer, investor and Board member. We thank Montserrat Vendrell, Partner at Alta Life Sciences and Aliath Bioventures for her productive tenure as Chairwoman since the inception of the company, and welcome Philippe’s guidance and expertise in translational drug development, financing and overall corporate strategy as we focus on developing our differentiated drug candidates to treat severe diseases of the central nervous system”, said Laurent NGUYEN, chief executive officer of Accure Therapeutics.

Currently, Dr. Philippe Monteyne is Partner with Aliath Bioventures, within AltamarCam Partners, in Barcelona. Before joining Aliath, Philippe was Senior Partner at Fund+, an open ended VC fund in Belgium, focusing on long-term equity investments with attractive returns in innovative life sciences companies across Europe. Philippe held board positions at Mynorix, Aelix, Ona Tx, Novadip, Exevir, Egle Tx and Coave Tx. His track record includes the contribution to very successful exits like Ogeda and Iteos.

Dr. Monteyne has a long-established professional experience in pharma, having been VP of R&D France at Sanofi and Head of Global Vaccines at GSK (overseeing the development of Cervarix eg, the cervical cancer vaccine), and Head of Development and Chief Medical Officer  at GSK Rare Diseases.

Philippe is a fully trained neurologist (M.D), with a PhD in viral immunology from Université Catholique de Louvain, a post-doc in neuroimmunology at Pasteur Institute (Paris) and an Advanced Management Programme from INSEAD.

“It is an incredibly exciting time at Accure Therapeutics as they advance their portfolio of novel, best-in-class peptidomimetics to treat CNS diseases including multiple sclerosis/optic neuritis, Parkinson’s diseases and epilepsy,” said Dr Monteyne. Accure Therapeutics is advancing the field of translational medicine in CNS with a high level of executional excellence, expertise and commitment. I’m honoured to work collaboratively with a Board and a leadership team that are inspired by and committed to their vision to transform patient health by delivering innovative disease modifying therapeutics.”

About Accure Therapeutics

Accure Therapeutics is a private translational neuroscience R&D company. Based in Barcelona (Spain), it was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I and supported by the Centre for Technological and Industrial Development (CDTI). This European company with an international mindset boasts a unique portfolio of three new chemical entity programs pursuing innovative targets – with potential to accommodate others. Accure aims to develop new disease modifying drugs to treat serious conditions such as optic neuritis, multiple sclerosis, Parkinson’s disease and epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.